Macrophage activation in human diseases

Seminars in Immunology

Volumn 27, Issue 4, 2015, Pages 249-256

  Schultze, Joachim L ^a   Schmieder, Astrid ^b   Goerdt, S ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Atopic dermatitis; Foam cell; Macrophage; Psoriasis; TAM; Tumor associated macrophages; Wound healing

Indexed keywords

ANIMAL; ATHEROSCLEROSIS; GENETIC EPIGENESIS; GENOMICS; HUMAN; HUMAN GENOME; IMMUNOLOGY; INFLAMMATION; MACROPHAGE ACTIVATION; NEOPLASM; OBESITY; WOUND HEALING;

ANIMALS; ATHEROSCLEROSIS; EPIGENESIS, GENETIC; GENOME, HUMAN; GENOMICS; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; NEOPLASMS; OBESITY; WOUND HEALING;

EID: 84939634903     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.07.003     Document Type: Review

References (101)

1. Heneka M.T., Kummer M.P., Latz E. Innate immune activation in neurodegenerative disease. Nature Rev. Immunol. 2014, 14:463-477.
2. Viola J., Soehnlein O. Atherosclerosis-a matter of unresolved inflammation. Semin. Immunol. 2015.
3. Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nature Rev. Immunol. 2015, 15:104-116.
4. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
5. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
6. Ginhoux F., Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nature Rev. Immunol. 2014, 14:392-404.
7. Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., et al. C-myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015, 42:665-678.
8. Perdiguero E.G., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2014.
9. Gosselin D., Link V.M., Romanoski Casey E., Fonseca Gregory J., Eichenfield Dawn Z., Spann Nathanael J., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014, 159:1327-1330.
10. Lavin Y., Winter D., Blecher-Gonen R., David E., Keren-Shaul H., Merad M., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014, 159:1312-1320.
11. Kohyama M., Ise W., Edelson B.T., Wilker P.R., Hildner K., Mejia C., et al. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 2009, 457:318-321.
12. Xue J., Schmidt S.V., Sander J., Draffehn A.M., Krebs W., Quester I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.
13. Schmieder A., Michel J., Schonhaar K., Goerdt S., Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin. Cancer Biol. 2012, 22:289-297.
14. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2796-2800.
15. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
16. Ostuni R., Kratochvill F., Murray P.J., Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015, 36:229-239.
17. Ruffell B., Coussens L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015, 27:462-472.
18. Dvorak H.F., Tumors: wounds that do not heal Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
19. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nature Rev. Immunol. 2011, 11:723-737.
20. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
21. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
22. Ojalvo L.S., King W., Cox D., Pollard J.W. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 2009, 174:1048-1064.
23. Torroella-Kouri M., Silvera R., Rodriguez D., Caso R., Shatry A., Opiela S., et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009, 69:4800-4809.
24. Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C.M., Pryer N., et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014, 26:623-637.
25. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009, 16:91-102.
26. Putoczki T.L., Thiem S., Loving A., Busuttil R.A., Wilson N.J., Ziegler P.K., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013, 24:257-271.
27. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
28. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2491-2496.
29. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
30. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
31. Shand F.H., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:7771-7776.
32. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
33. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. J. Virtual Lib. 2008, 13:453-461.
34. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 2010, 11:889-896.
35. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41.
36. Shalek A.K., Satija R., Shuga J., Trombetta J.J., Gennert D., Lu D., et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 2014, 510:363-369.
37. Shalek A.K., Satija R., Adiconis X., Gertner R.S., Gaublomme J.T., Raychowdhury R., et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013, 498:236-240.
38. Jaitin D.A., Kenigsberg E., Keren-Shaul H., Elefant N., Paul F., Zaretsky I., et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 2014, 343:776-779.
39. Zeisel A., Munoz-Manchado A.B., Codeluppi S., Lonnerberg P., La Manno G., Jureus A., et al. Brain structure Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 2015, 347:1138-1142.
40. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. Med. 1999, 340:115-126.
41. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
42. Glass C.K., Witztum J.L. Atherosclerosis-the road ahead. Cell 2001, 104:503-516.
43. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nature Rev. Immunol. 2013, 13:709-721.
44. Witztum J.L., Lichtman A.H. The influence of innate and adaptive immune responses on atherosclerosis. Annu. Rev. Pathol. 2014, 9:73-102.
45. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Rev. Immunol. 2007, 7:678-689.
46. Moore K.J., Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1702-1711.
47. van Gils J.M., Derby M.C., Fernandes L.R., Ramkhelawon B., Ray T.D., Rayner K.J., et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nature Immunol. 2012, 13:136-143.
48. Zhu X., Owen J.S., Wilson M.D., Li H., Griffiths G.L., Thomas M.J., et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 2010, 51:3196-3200.
49. Feng B., Yao P.M., Li Y., Devlin C.M., Zhang D., Harding H.P., et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nature Cell Biol. 2003, 5:781-792.
50. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
51. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nature Immunol. 2013, 14:812-820.
52. De Nardo D., Labzin L.I., Kono H., Seki R., Schmidt S.V., Beyer M., et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature Immunol. 2014, 15:152-160.
53. Feig J.E., Vengrenyuk Y., Reiser V., Wu C., Statnikov A., Aliferis C.F., et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PloS One 2012, 7:e39790.
54. Klein Allon M., Mazutis L., Akartuna I., Tallapragada N., Veres A., Li V., et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem, cells. Cell 2015, 161:1187-1201.
55. Robbins C.S., Hilgendorf I., Weber G.F., Theurl I., Iwamoto Y., Figueiredo J.L., et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nature Med. 2013, 19:1166-1172.
56. Gerrity R.G., Naito H.K. Lipid clearance from fatty streak lesions by foam cell migration. Artery 1980, 8:215-219.
57. Wanschel A., Seibert T., Hewing B., Ramkhelawon B., Ray T.D., van Gils J.M., et al. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 2013, 33:886-893.
58. Gast K.B., den Heijer M., Smit J.W., Widya R.L., Lamb H.J., de Roos A., et al. Individual contributions of visceral fat and total body fat to subclinical atherosclerosis: the NEO study. Atherosclerosis 2015, 241:547-554.
59. Biswas S.K., Mantovani A. Orchestration of metabolism by macrophages. Cell Metab. 2012, 15:432-437.
60. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89:2548-2556.
61. Vieira-Potter V.J. Inflammation and macrophage modulation in adipose tissues. Cell. Microbiol. 2014, 16:1484-1492.
62. Dalmas E., Clement K., Guerre-Millo M. Defining macrophage phenotype and function in adipose tissue. Trends Immunol. 2011, 32:307-314.
63. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (New York, NY) 2004, 306:457-461.
64. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
65. Murano I., Barbatelli G., Parisani V., Latini C., Muzzonigro G., Castellucci M., et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J. Lipid Res. 2008, 49:1562-1568.
66. Giordano A., Murano I., Mondini E., Perugini J., Smorlesi A., Severi I., et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J. Lipid Res. 2013, 54:2423-2436.
67. McNelis J.C., Olefsky J.M. Macrophages, immunity, and metabolic disease. Immunity 2014, 41:36-48.
68. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (New York, NY) 2011, 332:243-247.
69. Han M.S., Jung D.Y., Morel C., Lakhani S.A., Kim J.K., Flavell R.A., et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science (New York, NY) 2013, 339:218-222.
70. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nature Med. 2005, 11:191-198.
71. Chen A., Mumick S., Zhang C., Lamb J., Dai H., Weingarth D., et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obesity Res. 2005, 13:1311-1320.
72. Gutierrez D.A., Kennedy A., Orr J.S., Anderson E.K., Webb C.D., Gerrald W.K., et al. Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2-deficient mice delays improvements in insulin sensitivity. Diabetes 2011, 60:2820-2829.
73. Funk S.D., Orr A.W. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol. Res. Off. J. Italian Pharmacol. Soc. 2013, 67:42-52.
74. Mothe-Satney I., Filloux C., Amghar H., Pons C., Bourlier V., Galitzky J., et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes 2012, 61:2311-2320.
75. Schmieder A., Schaarschmidt M.L., Umar N., Terris D.D., Goebeler M., Goerdt S., et al. Comorbidities significantly impact patients' preferences for psoriasis treatments. J. Am. Acad. Dermatol. 2012, 67:363-372.
76. Nishimoto S., Kotani H., Tsuruta S., Shimizu N., Ito M., Shichita T., et al. Th17 cells carrying TCR recognizing epidermal autoantigen induce psoriasis-like skin inflammation. J. Immunol. 2013, 191:3065-3072.
77. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202:135-143.
78. Boehncke W.H., Schon M.P. Psoriasis. Lancet 2015.
79. Shlyankevich J., Mehta N.N., Krueger J.G., Strober B., Gudjonsson J.E., Qureshi A.A., et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am. J. Med. 2014, 127:1148-1150.
80. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch. Int. Med. 2007, 167:1670-1675.
81. Hamminga E.A., van der Lely A.J., Neumann H.A., Thio H.B. Chronic inflammation in psoriasis and obesity: implications for therapy. Med. Hypoth. 2006, 67:768-773.
82. Goldfine A.B., Buck J.S., Desouza C., Fonseca V., Chen Y.D., Shoelson S.E., et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diab. Care 2013, 36:4132-4139.
83. Dominguez H., Storgaard H., Rask-Madsen C., Steffen Hermann T., Ihlemann N., Baunbjerg Nielsen D., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 2005, 42:517-525.
84. Shafiq N., Malhotra S., Pandhi P., Gupta M., Kumar B., Sandhu K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int. J. Dermatol. 2005, 44:328-333.
85. Wang X.N., McGovern N., Gunawan M., Richardson C., Windebank M., Siah T.W., et al. A three-dimensional atlas of human dermal leukocytes, lymphatics, and blood vessels. J. Invest. Dermatol. 2014, 134:965-974.
86. Schledzewski K., Falkowski M., Moldenhauer G., Metharom P., Kzhyshkowska J., Ganss R., et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+ CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J. Pathol. 2006, 209:67-77.
87. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144:789-801.
88. Chen C.J., Kono H., Golenbock D., Reed G., Akira S., Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nature Med. 2007, 13:851-856.
89. Han B., Luo G., Shi Z.Z., Barrios R., Atwood D., Liu W., et al. Gamma-glutamyl leukotrienase, a novel endothelial membrane protein, is specifically responsible for leukotriene D(4) formation in vivo. Am. J. Pathol. 2002, 161:481-490.
90. Tamoutounour S., Guilliams M., Montanana Sanchis F., Liu H., Terhorst D., Malosse C., et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 2013, 39:925-938.
91. Daley J.M., Brancato S.K., Thomay A.A., Reichner J.S., Albina J.E. The phenotype of murine wound macrophages. J. Leuk. Biol. 2010, 87:59-67.
92. Brancato S.K., Albina J.E. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am. J. Pathol. 2011, 178:19-25.
93. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
94. Meszaros A.J., Reichner J.S., Albina J.E. Macrophage-induced neutrophil apoptosis. J. Immunol. 2000, 165:435-441.
95. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351.
96. Peters T., Sindrilaru A., Hinz B., Hinrichs R., Menke A., Al-Azzeh E.A., et al. Wound-healing defect of CD18(-/-) mice due to a decrease in TGF-beta1 and myofibroblast differentiation. EMBO J. 2005, 24:3400-3410.
97. Goren I., Allmann N., Yogev N., Schurmann C., Linke A., Holdener M., et al. A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am. J. Pathol. 2009, 175:132-147.
98. Sindrilaru A., Peters T., Wieschalka S., Baican C., Baican A., Peter H., et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 2011, 121:985-997.
99. Mirza R., Koh T.J. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine 2011, 56:256-264.
100. Sindrilaru A., Scharffetter-Kochanek K. Disclosure of the culprits: macrophages-versatile regulators of wound healing. Adv. Wound Care 2013, 2:357-368.
101. Scialdone A., Achim K., Marioni J.C. Single cell genomics meeting in stockholm: from single cells to cell types. Genome Biol. 2014, 15:496.